Hostname: page-component-77c89778f8-5wvtr Total loading time: 0 Render date: 2024-07-17T11:06:35.421Z Has data issue: false hasContentIssue false
  • English
  • Français

Protecting investments in polio eradication: the past, present and future of surveillance for acute flaccid paralysis

Published online by Cambridge University Press:  08 November 2004

D. L. HEYMANN ,
E. M. DE GOURVILLE  and
R. B. AYLWARD
D. L. HEYMANN
Affiliation:
Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
E. M. DE GOURVILLE
Affiliation:
Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
R. B. AYLWARD
Affiliation:
Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In September 2003 a WHO consultation group on vaccine-derived polioviruses (VDPV) concluded that in order to prevent future generations of paralytic polio after interruption of transmission of wild poliovirus, the use of trivalent oral polio vaccine (OPV) must be stopped [1]. Another important global policy decision along the road to polio eradication thus became possible – cessation of OPV use at some time after eradication. The question now is not whether OPV must be stopped, but rather when.

Type
Editorial
Information
Epidemiology & Infection , Volume 132 , Issue 5 , October 2004 , pp. 779 - 780
Copyright
© World Health Organization 2004

Footnotes

© World Health Organization 2004. The World Health Organization has granted Cambridge University Press permission for the reproduction of this article.